ABCAM Plc Directorate Change (2988D)
March 27 2014 - 3:00AM
UK Regulatory
TIDMABC
RNS Number : 2988D
ABCAM Plc
27 March 2014
For immediate release 27 March 2014
ABCAM PLC
("Abcam" or "the Company")
Appointment of Non-Executive Director
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of innovative protein research tools, is pleased to announce
the appointment of Lady Louise Patten as a Non-Executive Director
of the Company and as Chair of the Remuneration Committee with
immediate effect.
Louise brings extensive board level and corporate governance
experience, having served on quoted company boards for more than 20
years as a non-executive director, senior independent director,
remuneration committee chair and company chair at businesses
including the retailer Marks & Spencer plc, retailing group GUS
plc and hotelier Hilton Group plc.
Louise is currently a non-executive director of the FTSE-250
property group Intu Properties plc. She is also a senior adviser at
the management consultancy Bain & Company and a non-executive
director at the privately held risk consultancy Control Risks
Group, where she chairs the audit committee.
Mike Redmond, Abcam's Chairman, said: "I'm delighted to welcome
Louise Patten to Abcam as an independent Non-Executive Director.
Louise has extensive business and corporate governance experience
gained at substantial organisations. I am particularly pleased to
welcome Louise as Abcam's first female Board member. We look
forward to her input to the Board."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Lady Louise Alexandra
Virginia Patten, age 60 years, has been a director of the following
companies during the five years preceding the date of this
announcement:
Current directorships Past directorships
Intu Properties plc Brixton plc
Control Risks Group Holdings Marks & Spencer plc
Limited
UK Asset Resolution Limited
Bradford & Bingley plc
Northern Rock (Asset Management)
plc
There is no further information to be disclosed pursuant to Rule
17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
For further information please contact:
+ 44 (0) 1223 696
Abcam 000
Jeff Iliffe, Chief Financial Officer
Numis Securities - Nominated Adviser
& Joint Broker + 44 (0) 20 7260 1000
Michael Meade - Nominated Adviser
James Black - Corporate Broking
Peel Hunt LLP - Joint Broker + 44 (0) 20 7418 8900
Clare Terlouw / Jock Maxwell MacDonald
Buchanan + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie
Cowles
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and
services, with a wide range of products and expert technical
support, enabling scientists to analyse living cells at the
molecular level to improve the understanding of health and
disease.
Abcam is committed to providing scientists with access to the
correct reagents and tools for their research. The Company's
catalogue currently comprises more than 130,000 products and is
continually evolving to meet customer needs. The range offered
includes primary and secondary antibodies, proteins, peptides,
lysates, biochemicals, immunoassays and other kits. Abcam products
are supported with detailed, up-to-date and unbiased data on our
website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary
offices and ships to over 100 countries. The Company was founded in
1998 and now employs over 700 people. Abcam is quoted on the AIM
market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFMGZFMVGGDZZ
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024